Amended Statement of Beneficial Ownership (3/a)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC

2. Date of Event Requiring Statement (MM/DD/YYYY) 10/6/2021

3. Issuer Name and Ticker or Trading Symbol

Science 37 Holdings, Inc. [SNCE]

(Last) (First) (Middle)

929 NORTH FRONT STREET

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director ___X___ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

WILMINGTON, NC 28401

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)
10/18/2021

6. Individual or Joint/Group Filing(Check Applicable Line)

___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	17379797	D ⁽¹⁾⁽²⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:
(1)	These shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. are held of record by Pharmaceutical Product Development, LLC ("Pharma LLC"). Wildcat Acquisition Holdings (UK) Limited ("Wildcat") is the sole member of Pharma LLC; Jaguar Holding Company II ("Jaguar II") is the sole shareholder of Wildcat; Jaguar Holding Company I, LLC ("Jaguar I") is the sole shareholder of Jaguar II; Eagle Holding Company II, LLC ("Eagle II") is the sole member of Jaguar I; and PPD, Inc. is the sole member of Eagle II. By virtue of such relationships, each of the reporting persons may be deemed to have beneficial ownership over such shares of common stock.
(2)	This report on Form 3/A is jointly filed by the reporting persons. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein.

Remarks:
This Form 3/A amends and restates the original Form 3 filed by the Reporting Persons on October 18, 2021 (the "Original Form 3"). This amendment is being filed to correct the number of securities reported as beneficially owned by the Reporting Persons in the Original Form 3.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC 929 NORTH FRONT STREET WILMINGTON, NC 28401		X
Wildcat Acquisition Holdings (UK) Ltd 929 NORTH FRONT STREET WILMINGTON, NC 28401		X
Jaguar Holding Co II 929 NORTH FRONT STREET WILMINGTON, NC		X
Jaguar Holding Co I, LLC 929 NORTH FRONT STREET WILMINGTON, NC 28401		X
Eagle Holding Co II, LLC 929 NORTH FRONT STREET WILMINGTON, NC 28401		X
PPD, Inc. 929 NORTH FRONT STREET WILMINGTON, NC 28401		X

Signatures
Jaguar Holding Company II By: /s/ Julia James, Name: Julia James, Title: General Counsel and Secretary		11/8/2021
^**Signature of Reporting Person		Date
Eagle Holding Company II, LLC, By: /s/ B. Judd Harman, Name: B. Judd Hartman, Title: General Counsel and Secretary		11/8/2021
^**Signature of Reporting Person		Date
Pharmaceutical Product Development, LLC By: /s/ Julia James, Name: Julia James, Title: EVP, General Counsel and Secretary		11/8/2021
^**Signature of Reporting Person		Date
Jaguar Holding Company I, LLC By: Eagle Holding Company II, LLC, By: /s/ B. Judd Harman, Name: B. Judd Hartman, Title: General Counsel and Secretary		11/8/2021
^**Signature of Reporting Person		Date
Wildcat Acquisition Holdings (UK) Limited By: /s/ B. Judd Hartman, Name: B. Judd Hartman, Title: Director		11/8/2021
^**Signature of Reporting Person		Date
PPD, Inc. By: /s/ Julia James, Name: Julia James, Title: EVP, General Counsel and Secretary		11/8/2021
^**Signature of Reporting Person		Date